Abel S, Hasan S, Verma V, et al. - Given that the biological effective dose (BED) escalation above 100 Gy₁₀ improves tumor control, researchers identified the optimal dose threshold for squamous cell carcinoma (SCC) and adenocarcinoma (ADC) via using receiver operator characteristic curve analysis. Patients with SCC or ADC treated with stereotactic ablative radiotherapy (SABR) were consulted for the National Cancer Database for ES-NSCLC (T1-2N0, Stage I-IIA). Study participants were stratified by histology and BED (≥ 122 Gy₁₀ vs < 122 Gy₁₀). In the final analysis, 11,084 ES-NSCLC patients were eligible for either ADC (n = 6,476) or SCC (n = 4,608). For both SCC and ADC, calculated optimal BED threshold was 122 Gy₁₀. In patients with SCC of the lung post-SABR, escalation of BED ≥ 122 Gy₁₀ was an independent prognosticator of improved survival. There was no survival benefit for ADC, indicating a differential response to BED escalation.